Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (3): 540-549    DOI: 10.31083/j.ceog.2021.03.2347
Original Research Previous articles | Next articles
Pegylated-interferon-alpha treatment modulating the immune response of cytotoxic lymphocytes in cervical intraepithelial neoplasia
Letícia Montes Stark1, Rosekeila Simões Nomelini1, 2, Marco Aurélio Trovó2, Márcia Antoniazi Michelin1, 3, Eddie Fernando Candido Murta1, 2, *()
1Oncology Research Institute (IPON), Federal University of the Triângulo Mineiro (UFTM), 38025-440 Uberaba, Minas Gerais, Brazil
2Department of Gynecology and Obstetrics, Federal University of the Triângulo Mineiro (UFTM), 38071-200 Uberaba, Minas Gerais, Brazil
3Discipline of Immunology, Federal University of the Triângulo Mineiro (UFTM), 38071-200 Uberaba, Minas Gerais, Brazil
Download:  PDF(3476KB)  ( 54 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Interferons are inducible secretory glycoproteins with immunomodulators, antiviral, antiangiogenic and antiproliferative effects. Evaluate the mechanisms responsible by regression of patients diagnosed with Cervical Intraepithelial Neoplasia (CIN) and treated with IFN-α, systemically and locally, by Interferon-α (IFN-α) receptor 1 (IFNR1) and IFN-α receptor 2 (IFNR2) and transcription factors STAT-1 (Signal Transducers and Activators of Transcription 1) and IRF-7 (Interferon Regulatory Factor 7), as well as the endogenous produced IFN-α by total (CD3+), Helper (CD4+), cytotoxic (CD8+) T lymphocytes and monocytes (CD14+). Methods: A prospective study was developed in which eighteen patients diagnosed with CIN II/III in treatment protocol with Peginterferon-α. Cells were evaluated using Real-Time and flow cytometry, and the data were analyzed using Kruskal-Wallis and ANOVA tests, considering p ≤ 0.05. Results: Eight patients obtained regression of the lesion, and ten did not obtain the regression. Patients who did respond positively to the treatment presented a CD8+ T lymphocyte with IFN-α increase when compared to patients who not responded positively. When analyzing CD8+ T lymphocytes during the stages of treatment in lesion regression, it is observed a significant IFNR1 (p = 0.0391) decrease in patients who did not achieve lesion regression. CD3 and CD14 data was not significant. Discussion: Immunomodulation by Interferon-alpha seems to depend on the systemic expression of IFN receptors. Our data suggest that patients who can respond to immunotherapy already have a pattern of IFN receptor expression in lymphocytes, which contributes to successful treatment.
Key words:  Immunotherapy      Interferon-α      Cervical intraepithelial neoplasia     
Submitted:  04 November 2020      Revised:  15 February 2021      Accepted:  05 March 2021      Published:  15 June 2021     
Fund: 
Studies and Projects Funding Body (FINEP)
National Council for Scientific and Technical Development (CNPq)
Uberaba Foundation for Teaching and Research (FUNEPU)
CDS-RED-00011-14/Foundation for Research Assistance of the State of Minas Gerais (FAPEMIG)
*Corresponding Author(s):  Eddie Fernando Candido Murta     E-mail:  eddiemurta@mednet.com.br

Cite this article: 

Letícia Montes Stark, Rosekeila Simões Nomelini, Marco Aurélio Trovó, Márcia Antoniazi Michelin, Eddie Fernando Candido Murta. Pegylated-interferon-alpha treatment modulating the immune response of cytotoxic lymphocytes in cervical intraepithelial neoplasia. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 540-549.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.03.2347     OR     https://ceog.imrpress.com/EN/Y2021/V48/I3/540

No related articles found!
No Suggested Reading articles found!